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Stephen M. Krane, MD^

fd. Note - This overview was originally presented at the
International Symposium on Clinical Disorders of Bone
and Mineral Metabolism, May 9-13,1983. The following
list indicates the presentations given in this session at the
Symposium and the contents ofthe corresponding
chapter in the Proceedings of the Symposium published by
Excerpta Medica. The numbers in parentheses refer to
pages in this volume. Complete information about the
contents of the Proceedings can be found at the back of
this issue.

Essential to understandingthe pathophysiology of skeletal diseases and evaluating the results of therapy are
markers for bone cell function and a means to accurately
measure the synthesis and degradation o f t h e extracellular matrix of bone. As knowledge has advanced concerning the structure and composition of bone and pathways
of biosynthesis o f t h e skeletal components, new markers
have become available. The utility of techniques that
have been used for years to quantitate bone formation
and resorption now have a different perspective.

Tracer measurements of bone remodeling and their significance in involutional osteoporosis. J. Reeve, M .
Arlot, R. Hesp, M . Tellez, and P.J. Meunier (99)
Excretion of urinary hydroxyproline peptides in the
assessment of bone collagen deposition and resorption.
K.I. Kivirikko (105)
Procollagen extension peptides as markers of collagen
synthesis. L.S. Simon and S.M. Krane (108)

Over the past several years, several noncollagenous proteins unique to bone have been identified and characterized. The isolation of the a-carboxyglutamic acid (Gla)
protein (osteocalcin), osteonectin, and bone proteoglycan has been made possible by avoiding artifacts introduced by mechanical shearing forces that cause release
of proteases during demineralization and extraction.
Osteonectin is a good example (4,5). It represents more
TABLE I
Composition of the Organic Matrix of Bone

Bone is a two phase material composed of an inorganic
mineral phase (~65% of weight) and an organic matrix
(—35% of weight). The calcium-phosphorus mineral
phase, at least part of which is organized with respect to
the collagenous portion o f t h e organic matrix, consists of
poorly crystalline hydroxyapatite (1). The composition of
the organic matrix of bone is described in Table I.
The collagen of bone is almost exclusively type I, identical
in primary structure to the type I collagen in other organs
(2). However, there are differences in certain posttranslational modifications between the type I collagens in skin
and bone, particularly with respect to content of hydroxylysine, hydroxylysine glycosides, and the hydroxylysinederived hydroxypyridinium crosslinks (3). The distinctive
collagenous product o f t h e osteoblast can thus be ascribed
to the expression of genes coding for proteins other than
the component o:1(l) and cr2(l) chains.

I. Type I collagen: 90-95% of total
II. Noncollagenous proteins
A.

' ' T r u e " matrix constituents (osteoblast-derived)
1. Osteonectin

2. Bone sialoprotein
3. Bone proteoglycan

4. Other glycoproteins
5. Phosphoproteins
B.

Bound to mineral phase (osteoblast-derived)
1. Bone Gla protein (osteocalcin)

C.

Serum-derived
1. cr^-HS glycoprotein
2. Other serum proteins
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t h a n 2 5 % of t h e n o n c o l l a g e n o u s p r o t e i n s o f

bovine

bone. Osteonection, which is made by osteoblasts, may
have a functional as well as structural role in regulating
collagen and protein synthesis. Radioimmunoassays developed for this protein should serve as another marker
for matrix protein metabolism in humans.
I n t h e process of bone formation, mineral ions enter the
inorganic phase and are removed in the process of bone
resorption. Thus, the kinetics of rad local cium and radiostrontrium uptake by the skeleton provide a means to
quantitate bone formation and resorption. Validation of
the derived rates is best accomplished by employing an
independent method. In this Symposium, Reeve and
associates (pp. 99 ff.) have described histomorphometric
methods with double tetracycline labeling to calculate
local bone formation rates. These correlate with whole
body radiotracer data that are properly corrected for
long-term exchange processes.
As suggested in Fig. 1, the synthetic activities of osteoblasts might be monitored without direct bone sampling
if byproducts of the matrix components that become
part of bone were released quantitatively and easily
measured. Moreover, the release of degradation products of bone resorption could provide an accurate
index of these processes. Considerable effort has been
devoted to the measurements of collagen-related markers.
Many investigators have relied on measurement of urinary hydroxyproline excretion to evaluate metabolic
bone diseases. Unfortunately, total urinary hydroxyproline represents only 10-20% of that released from collagen degradation, since free hydroxyproline released
from collagen-derived oligopeptides is oxidized to a
number of other products. In individuals w h o excrete
relatively low amounts of urinary hydroxyproline, e.g.,
osteoporotics, a minor change in catabolism resulting
from therapy could produce major changes in hydroxyproline excretion. Furthermore, significant amounts of

urinary h y d r o x y p r o l i n e are d e r i v e d f r o m collagen
sequences other than bone, particularly in those individuals excreting less than 40 mg/day. For these reasons,
other measurements have been used. Measurement of
hydroxylysine and its glycosides more accurately reflects
the amount and source of collagen degradation. Although
these methods are tedious, they are constantly being
modified. Kivirikko's review (pp. 105 ff.) discussed the
measurement of serum levels of posttranslational
collagen-modifying enzymes in disease states.
Collagens are synthesized as procollagens, which are
molecules with extra sequences at either end that must
be cleaved when the mature fibril is formed extracellularly. Simon and I (pp. 108 ff.) discussed the use of
radioimmunoassays for two of the procollagen extensions to evaluate changes in Paget's disease and other
conditions. The procollagen extensions are examples of
byproducts of synthesis (Fig.1). The aminoterminal peptides may have a regulatory role in the feedback control
of collagen formation.
A radioimmunoassay of bone Gla protein has recently
been developed to detect markers for the noncollagenous proteins of bone. This 49-amino acid polypeptide is
produced by osteoblasts, and its rate of synthesis is subject to endocrine control. Probably synthesized at some
stage in bone formation later than that of noncollagenous proteins such as osteonectin, its role in bone remains
to b e d e f i n e d . Nevertheless, this Gla protein is u n i q u e t o
bone and circulates in normal human plasma. Moreover,
as discussed by Deftos and Catherwood (pp. 112 ff.)
circulating levels change in bone diseases and in response
to alterations in parathyroid hormone secretion. Whether
levels of bone Gla protein reflect bone formation primarily or resorption remains to be determined.
Several noncollagenous proteins of bone that are not
produced by bone cells, such as albumin and Oj-yiS
glycoprotein, become part of the extracellular matrix in
the course of bone formation. The a2-HS glycoprotein is
synthesized in the liver, released into the circulation,
and selectively taken up by bone. Thus, levels of this
protein in plasma might reflect inversely the rate of bone
formation. Smith, et al (pp. 116 ff.) discussed their results
using a radioimmunoassay for aj-HS glycoprotein in
patients with metabolic bone diseases. The direction of
change in levels of the protein was as predicted, but the
change was not great enough for the measurement to be
widely adopted.
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To quantitate bone formation, it w o u l d be highly desirable to have a measurement that reflects osteoblastic
activity directly. Measurements of circulating alkaline

Fig.1
Schematic Representation of Bone Formation and Resorption.
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phosphatase activity have been available for over 50
years. Bone is rich in this enzyme, which is localized
predominantly in osteoblasts. Despite this evidence, the
role of alkaline phosphatase in bone formation has yet to
be defined. As discussed by Whyte (pp. 120 ff.), the
enzyme in bone can be distinguished f r o m that in other
tissues by immunological and kinetic methods.

Considerable progress has been made to develop markers
for bone formation and resorption that do not depend
on bone biopsy. In the future, many methods for measuring these markers, which are currently being developed, should provide accurate, quantitative information
for diagnosis, understanding the pathophysiology of
metabolic bone diseases, and evaluation of therapy.
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